Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial

Published:2018-03-01 Issue:10 Volume:20 Page:1447-1453
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Banke Ann¹,Fosbøl Emil L.²,Møller Jacob E.¹,Gislason Gunnar H.³⁴,Andersen Mads⁵,Bernsdorf Mogens⁶,Jensen Maj-Britt⁷,Schou Morten⁸,Ejlertsen Bent⁶⁷

Affiliation:

1. Department of Cardiology; Odense University Hospital; Odense Denmark

2. Department of Cardiology; Rigshospitalet; Copenhagen Denmark

3. Department of Cardiology; Herlev and Gentofte University Hospital; Hellerup Denmark

4. The Danish Heart Foundation; Copenhagen Denmark

5. Department of Cardiology; Aarhus University Hospital; Aarhus Denmark

6. Department of Oncology; Rigshospitalet; Copenhagen Denmark

7. Danish Breast Cancer Cooperative Group; Rigshospitalet; Copenhagen Denmark

8. Department of Cardiology; Herlev and Gentofte University Hospital; Herlev Denmark

Funder

Danish Heart Foundation and the Research Fund

Novo Nordisk Fonden

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ejhf.1168/fullpdf

Reference23 articles.

1. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality;Youlden;Cancer Epidemiol,2012

2. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer;Ejlertsen;Eur J Cancer,2007

3. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5;Levine;J Clin Oncol,2005

4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group (EBCTGG);Lancet,2005

5. Risk factors for doxorubicin-induced congestive heart failure;Von Hoff;Ann Intern Med,1979

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis;Heart;2024-08-22

2. Betaine alleviates doxorubicin-related cardiotoxicity via suppressing oxidative stress and inflammation via the NLRP3/SIRT1 pathway;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-02

3. Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging;Journal of Clinical Medicine;2024-06-26

4. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors;Journal of Clinical Oncology;2024-06-04

5. Chinese medicinal formula Fu Xin decoction against chronic heart failure by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway;Biomedicine & Pharmacotherapy;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3